



1st edition

Dubaï **Qatar**



Better understand the Lipids Guidelines Development Process







Know more about

Lipids Guidelines development process and its implications

The Translational Medicine Academy (TMA) is an international academic Foundation with focused activities in Mission Critical Areas of high public health importance having significant professional and patient therapeutic and educational gaps.

Why a Lipid Guidelines Forum®?

Hyperlipidemia is a common modifiable risk factor for atherosclerotic cardiovascular disease. LDL cholesterol is the lipid fraction that has been the focus for risk assessment and

Guidelines for the prevention of atherosclerotic cardiovascular disease vary among national societies. One approach emphasizes treatment based on the LDL cholesterol concentration, and the other approach is based on strict interpretation of randomized clinical trials that emphasize high intensity statin therapy for patients with atherosclerotic cardiovascular disease and moderate intensity statin therapy for patients with diabetes and high 10-year risk of coronary heart disease events. These different approaches have resulted in confusion for healthcare professionals and patients.

The application of risk tools validated in certain races and ethnicities in Western countries may not be valid for other countries with different genetics, environment and co-morbidities. Efforts are needed to organize prospective population cohorts in order to develop country and region specific risk assessment tools.

Low adherence to evidence based therapies remains another major challenge to the effective implementation of treatment guidelines. Strategies to improve treatment adherence involve many aspects of the healthcare system including the system, provider and patient.

Accordingly, the process of guidelines elaboration needs critical improvements to improve implementation of guidelines by healthcare professionals and improve understanding of the benefits of preventive care and treatment adherence among patients.

Forum objectives

To have an in depth discussion between experts about Lipids therapy guidelines for the common interest of stakeholders during a closed meeting

- To focus on most advanced knowledge
- To identify gaps in treatment
- To improve the development and utilization of guidelines
- To develop "field guidelines" that are applicable to ethnically and racially diverse populations with different co-morbidities and hypertension profiles
- To develop risk equations for specific geographies/populations
- To create genetic profiles for specific geographies/populations to better understand responsiveness to therapies

Format

A series of short presentations and discussions with a focus on practical examples, case studies and interactivity between Faculty members.

Who should attend?

Industry representatives, clinical research organizations, health insurance system professionals, pharmacy benefits managers and all those interested in Primary Hypertension from a scientific, regulatory, educational and cost-benefit management perspective.





An opportunity to meet a panel of international scientific experts

GUIDELINES FORUM® CO-CHAIRS

(To be conirmed)



Prof. Robert Rosenson

MD – Icahn School of Medicine at Mount Sinai FACC, FACP, FAHA, FESC, FNLA, FACCP New York Director of Cardiometabolic Disorders. He is a Fellow of the American Heart Association Council on Epidemiology and Prevention. Fellow of the American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology, Fellow of the National Lipid Association.

Immediate past President of the International Atherosclerosis Society. He has held positions in research institutes and universities in Australia and the US and is currently based at the University of New South Wales in Australia. He is a fellow of the Royal Australasian College of Physicians.

Prof. Philip Barter

MD – University of New South Wales Australia





Prof. Erik Stroes

MD PhD, Professor Academic Medical Center Amsterdam, The Netherlands Chair department of Vascular Medicine, he is one of the AMC Principal Investigators. Member of the clinical Advisory Board AtheroNova Inc., He also joined the scientific advisory board of the Cardiology Online Inc. and of the Colt Resources Inc.

Why attend a Guidelines Forum®?

At the end of the meeting, all participants will have a better understanding of the unmet needs and knowledge gaps that need to be addressed by future research and development efforts, and of the most appropriate ways of progressing to conciliate and take advantage of clinical, societal, evidence-based medicine and regulatory requirements.

3



Preliminary Agenda

- Guidelines development process
- Guidelines and awareness campaigns
- Lipids management recommendations
- Lipids prevention recommendations
- Specific patient populations
- Guidelines implementation
- Case-based discussions and scenarios
- Health economic perspectives
- Latest clinical developments

Faculty

It will include a Faculty of 15 experts, either international guideline writers, reviewers and independent experts, as well as regulatory representatives from Europe, North America and Asia.

Presentations are not handed out and there will be no published proceedings.

Interested in going further on Lipids?

Ongoing programs

Participate in post forum activities with TMA.

We offer you the opportunity to go further on Prevention and Management with our dedicated programs (part of TMA Mission Areas plans).

Our team can propose you the most convenient activities, that TMA is developing, on request.

Contact us

TMA Foundation

Charles Schoen - Operations Director

Tel.: +33 (0) 6 08 18 77 08

Email: charles.schoen@tmacademy.org

Grant Opportunities (including CME, Advisory Boards

& Customized Grants)

Yann Colardelle / William Melhuish

Tel.: + 33 (0) 6 16 54 81 57

E-mail: william@mededgs.com and

yanncol@tmacademy.org

Organization:

Anne-Sophie Squiban

Tel: + 33 (0)6 74 52 37 09

Email: appasablia squiban@tmasadamy.org



Registration: www.tmacademy.org